Senvelgo® oral solution
A breakthrough in feline diabetes management
Feline diabetes mellitus is a common endocrine disorder characterised by persistent hyperglycaemia due to impaired insulin production or insulin resistance. Without effective management, it can lead to polyuria, polydipsia, weight loss and reduced quality of life.
Management has traditionally relied on twice-daily insulin injections and careful monitoring. Senvelgo® lowers blood glucose by increasing urinary glucose excretion, offering a once-daily, injection-free treatment option for appropriate feline patients. It is available in 12 ml and 30 ml bottle sizes to support both initiation and ongoing therapy.
How Senvelgo® works
Senvelgo® (velagliflozin) is an oral SGLT-2 inhibitor designed specifically for feline diabetes. Rather than replacing insulin, it works through a different pathway to reduce hyperglycaemia.
Its mode of action includes:
- Inhibition of SGLT-2 in the kidneys reduces reabsorption of glucose from the renal filtrate
- Increased urinary glucose excretion lowers circulating blood glucose levels
- Which relieves glucose toxicity
- This enables improved beta cell function and increased endogenous insulin production
- Resulting in diabetic control
96% of veterinary professionals agree Senvelgo® improved diabetic cats' and owners' quality of life
Between November 2024 and February 2025, we surveyed hundreds of veterinary professionals and pet owners about their experience of using Senvelgo®. The message that came back was clear: Senvelgo® is delivering positive experiences for veterinary professionals and cat owners around the world.
Veterinary Support
Our Pet Technical Services Team of veterinary surgeons and veterinary nurses are committed to helping you provide the best veterinary care through the provision of product advice and clinical case discussion.
